11 research outputs found
Efecto de la adición de ácido cítrico y la cantidad de yeso sobre las propiedades del cemento de sulfoaluminato de calcio
No full textThe influence of citric acid on the hydration and strength development of a calcium sulphoaluminate cement was investigated. Cement pastes were prepared by mixing calcium sulphoaluminate (C4A3Ŝ) with 15, 20 and 25wt% of hemihydrate (CŜH0.5). Citric acid was added as a retarder at 0 and 0.5wt%. The samples were cured at 20 °C for periods of time from 1 to 28 days to evaluate their compressive strength and to characterize the hydration products by scanning electron microscopy and X-ray diffraction. Calorimetric curves showed that the retarding agent considerably decreases the heat release rate and the quantity of total heat released. The main product after the curing was ettringite (C6AŜ3H32). The morphology of this phase consisted of long and thin needles growing radially on the cement grains. Samples with 15wt% of hemihydrate and 0.5wt% of citric acid developed the highest compressive strength (70 MPa) at 28 days of curing.Se investigó el efecto del ácido cítrico sobre la hidratación y propiedades mecánicas de un cemento de sulfoaluminato de calcio. El C4A3Ŝ se mezcló con 15, 20 y 25% e.p. de hemihidrato (CŜH0.5). Se agregó ácido cítrico como retardante en 0 y 0.5% e.p. Las muestras fueron curadas a 20 °C por periodos de 1 a 28 días para realizar mediciones de resistencia a la compresión y caracterizar los productos de hidratación mediante microscopía electrónica de barrido y difracción de rayos X. Las curvas de calorimetría mostraron ue el ácido cítrico disminuye la velocidad de liberación de calor y la cantidad de calor liberado durante la hidratación. La resistencia a la compresión alcanzó un máximo de 70 MPa en muestras con 15% e.p. de hemihidrato y 0,5% e.p de ácido cítrico. Los resultados muestran a la etringita (C6AŜ3H32) como principal producto de hidratación. Se observa a esta fase con morfología acicular creciendo sobre las partículas de cemento
Efecto del contenido de aluminato de estroncio y hemihidrato sobre las propiedades de un cemento de sulfoaluminato de calcio
No full textThe effect of strontium aluminate (SrAl2O4) on the hydration process of a calcium sulphoaluminate (C4A3Ŝ) cement was investigated. Cement pastes were prepared by mixing C4A3Ŝ , hemihydrate (CaSO4· ½H2O, CŜH0.5) and 0, 10 or 20wt% of SrAl2O4 (SrA). The amount of CŜH0.5 was 15, 20 or 25wt% based on the C4A3Ŝ quantity. The cement pastes were hydrated using water to cement ratios (w/c) of 0.4 and 0.5. Samples were cured from 1 to 28 d. The compressive strength and setting time were evaluated and the hydration products were characterized. It was found that the setting time was delayed up to 42 min for the samples containing SrAl2O4 compared to samples without addition. The samples with 25wt% hemihydrate containing 20wt% SrAl2O4 developed the highest compressive strength (60 MPa) after 28 d of curing. The main product after hydration was ettringite (C6AŜ3H32). The morphology of this phase consisted of thin needle-shaped crystals.Se investigó el efecto de la adición de aluminato de estroncio (SrAl2O4) sobre las propiedades de un cemento de sulfoaluminato de calcio (C4A3Ŝ). Se prepararon muestras mezclando C4A3Ŝ, hemihidrato (CaSO4· ½H2O, CŜH0.5) y 0, 10 o 20% e.p de SrAl2O4 (SrA). La cantidad de CŜH0.5 fue de 15, 20 o 25% e.p. basado en la cantidad de C4A3Ŝ. Las relaciones agua/cemento utilizadas fueron 0.4 y 0.5. Las muestras fueron curadas hasta 28 d. Se evaluó el tiempo de fraguado y la resistencia a la compresión. Los productos de hidratación se caracterizaron mediante DRX y MEB. El tiempo de fraguado se retardó hasta 42 minutos con la adición del SrAl2O4 comparado con las muestras sin adiciones. Las muestras con 25% e.p. de yeso y 20% e.p. de SrAl2O4 desarrollaron la mayor resistencia a la compresión alcanzando 60 MPa a 28 d de curado. Los análisis por MEB y DRX muestran como principal producto de hidratación a la etringita (C6AŜ3H32), cuya morfología se observa como cristales aciculares
Small patches of riparian woody vegetation enhance biodiversity of invertebrates
No full textPatches of riparian woody vegetation potentially help mitigate environmental impacts of agriculture and safeguard biodiversity. We investigated the effects of riparian forest on invertebrate diversity in coupled stream-riparian networks using a case study in the Zwalm river basin (Flanders, Belgium). Agriculture is one of the main pressures in the basin and riparian forest is limited to a number of isolated patches. Our 32 study sites comprised nine unshaded “unbuffered” sites which were paired with nine shaded “buffered” sites on the same stream reach, along with five ‘least-disturbed’ sites and nine downstream sites. We sampled water chemistry, habitat characteristics and stream and riparian invertebrates (carabid beetles and spiders) at each site. Three methods were used to quantify riparian attributes at different spatial scales: a visually-assessed qualitative index, quantitative estimates of habitat categories in six rectangular plots (10 × 5 m) and geographic information system (GIS)-derived land cover data. We investigated relationships between invertebrates and riparian attributes at different scales with linear regression and redundancy analyses. Spiders and carabids were most associated with local riparian attributes. In contrast, aquatic macroinvertebrates were strongly influenced by the extent of riparian vegetation in a riparian band upstream (100–300 m). These findings demonstrate the value of quantifying GIS-based metrics of riparian cover over larger spatial scales into assessments of the efficacy of riparian management as a complement to more detailed local scale riparian assessments in situ. Our findings highlight the value of even small patches of riparian vegetation in an otherwise extensively disturbed landscape in supporting biodiversity of both terrestrial and freshwater invertebrates and emphasize the need to consider multiple spatial scales in riparian management strategies which aim to mitigate human impacts on biodiversity in stream-riparian networks
Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
No full textBackground
The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea.
Methods
We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up.
Findings
We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission).
Interpretation
Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19.
Funding
PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.
COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders
ВЛИЯНИЕ МАГНИТНОГО ПОЛЯ НА ПРОЦЕСС КРИСТАЛЛИЗАЦИИ АЛЮМИНИЕВЫХ РАСПЛАВОВ
No full textConscious management of metal crystallization processes in order to obtain a defined ingot microstructure is provided by using various physical fields. These fields affect the melt and change its internal state, and therefore its crystallization kinetics. The paper describes the thermodynamics and kinetics of aluminum crystallization when the melt is treated with magnetic field. A quite simple experimental setup is created to allow studying the magnetic field effect on molten aluminum or other metals and alloys. It consists of several main components: (1) electrical furnace; (2) water-cooled copper crucible combined with an electromagnetic coil; (3) mechanical device for rapid movement of the aluminum melt crucible; (4) system for melt temperature monitoring and control and (5) electronics for data recording and processing. It is experimentally proved that magnetic field changes the melt-crystal phase equilibrium temperature, latent heat of phase transition and temperature of melt supercooling at crystallization. It is shown that changes in these parameters reduce the radius of critical nuclei and increases the speed of their origin. Temperature-time relationship are obtained for the crystallization process. It is experimentally proved that aluminum melt treatment with magnetic field reduces the time of crystallization. The analysis of aluminum samples obtained under the influence of magnetic field has shown that their structure has more fine grains compared with untreated samples.Для сознательного управления процессом кристаллизации металлов с целью получения заданной микроструктуры слитка используют различные физические поля, которые при воздействии на расплав изменяют его внутреннее состояние, а значит, и кинетику кристаллизации. В работе описаны термодинамика и кинетика процесса кристаллизации алюминия при обработке расплава магнитным полем. Создана достаточно простая экспериментальная установка, позволяющая изучать процессы воздействия магнитного поля на расплавы алюминия или других металлов и сплавов. Она состоит из нескольких основных узлов: (1) электропечи; (2) водоохлаждаемого медного кристаллизатора, совмещенного с электро- магнитной катушкой; (3) механического устройства для быстрого перемещения тигля с расплавом алюминия; (4) системы контроля и управления температурой расплава; (5) электронной части для записи и обработки информации. Экспериментально установлено, что магнитное поле изменяет температуру фазового равновесия расплав–кристалл, скрытую теплоту фазового перехода и температуру переохлаждения расплава при кристаллизации. Показано, что изменение этих параметров приводит к уменьшению радиуса критических зародышей и увеличению скорости их зарождения. Получены температурно-временные зависимости процесса кристаллизации. Выявлено, что при обработке расплава алюминия магнитным полем время кристаллизации уменьшается. Анализ алюминиевых образцов, полученных под воздействием магнитного поля, показал, что их структура имеет более мелкие зерна, чем у образцов, не подверженных такой обработке
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
No full textBackground:
Sleep disturbance is common following hospital admission both for COVID-19 and other causes. The clinical associations of this for recovery after hospital admission are poorly understood despite sleep disturbance contributing to morbidity in other scenarios. We aimed to investigate the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and to assess whether this was associated with dyspnoea.
Methods:
CircCOVID was a prospective multicentre cohort substudy designed to investigate the effects of circadian disruption and sleep disturbance on recovery after COVID-19 in a cohort of participants aged 18 years or older, admitted to hospital for COVID-19 in the UK, and discharged between March, 2020, and October, 2021. Participants were recruited from the Post-hospitalisation COVID-19 study (PHOSP-COVID). Follow-up data were collected at two timepoints: an early time point 2–7 months after hospital discharge and a later time point 10–14 months after hospital discharge. Sleep quality was assessed subjectively using the Pittsburgh Sleep Quality Index questionnaire and a numerical rating scale. Sleep quality was also assessed with an accelerometer worn on the wrist (actigraphy) for 14 days. Participants were also clinically phenotyped, including assessment of symptoms (ie, anxiety [Generalised Anxiety Disorder 7-item scale questionnaire], muscle function [SARC-F questionnaire], dyspnoea [Dyspnoea-12 questionnaire] and measurement of lung function), at the early timepoint after discharge. Actigraphy results were also compared to a matched UK Biobank cohort (non-hospitalised individuals and recently hospitalised individuals). Multivariable linear regression was used to define associations of sleep disturbance with the primary outcome of breathlessness and the other clinical symptoms. PHOSP-COVID is registered on the ISRCTN Registry (ISRCTN10980107).
Findings:
2320 of 2468 participants in the PHOSP-COVID study attended an early timepoint research visit a median of 5 months (IQR 4–6) following discharge from 83 hospitals in the UK. Data for sleep quality were assessed by subjective measures (the Pittsburgh Sleep Quality Index questionnaire and the numerical rating scale) for 638 participants at the early time point. Sleep quality was also assessed using device-based measures (actigraphy) a median of 7 months (IQR 5–8 months) after discharge from hospital for 729 participants. After discharge from hospital, the majority (396 [62%] of 638) of participants who had been admitted to hospital for COVID-19 reported poor sleep quality in response to the Pittsburgh Sleep Quality Index questionnaire. A comparable proportion (338 [53%] of 638) of participants felt their sleep quality had deteriorated following discharge after COVID-19 admission, as assessed by the numerical rating scale. Device-based measurements were compared to an age-matched, sex-matched, BMI-matched, and time from discharge-matched UK Biobank cohort who had recently been admitted to hospital. Compared to the recently hospitalised matched UK Biobank cohort, participants in our study slept on average 65 min (95% CI 59 to 71) longer, had a lower sleep regularity index (–19%; 95% CI –20 to –16), and a lower sleep efficiency (3·83 percentage points; 95% CI 3·40 to 4·26). Similar results were obtained when comparisons were made with the non-hospitalised UK Biobank cohort. Overall sleep quality (unadjusted effect estimate 3·94; 95% CI 2·78 to 5·10), deterioration in sleep quality following hospital admission (3·00; 1·82 to 4·28), and sleep regularity (4·38; 2·10 to 6·65) were associated with higher dyspnoea scores. Poor sleep quality, deterioration in sleep quality, and sleep regularity were also associated with impaired lung function, as assessed by forced vital capacity. Depending on the sleep metric, anxiety mediated 18–39% of the effect of sleep disturbance on dyspnoea, while muscle weakness mediated 27–41% of this effect.
Interpretation:
Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.
Funding:
UK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyResearch in context
No full textSummary: Background: The scale of COVID-19 and its well documented long-term sequelae support a need to understand long-term outcomes including frailty. Methods: This prospective cohort study recruited adults who had survived hospitalisation with clinically diagnosed COVID-19 across 35 sites in the UK (PHOSP-COVID). The burden of frailty was objectively measured using Fried's Frailty Phenotype (FFP). The primary outcome was the prevalence of each FFP group—robust (no FFP criteria), pre-frail (one or two FFP criteria) and frail (three or more FFP criteria)—at 5 months and 1 year after discharge from hospital. For inclusion in the primary analysis, participants required complete outcome data for three of the five FFP criteria. Longitudinal changes across frailty domains are reported at 5 months and 1 year post-hospitalisation, along with risk factors for frailty status. Patient-perceived recovery and health-related quality of life (HRQoL) were retrospectively rated for pre-COVID-19 and prospectively rated at the 5 month and 1 year visits. This study is registered with ISRCTN, number ISRCTN10980107. Findings: Between March 5, 2020, and March 31, 2021, 2419 participants were enrolled with FFP data. Mean age was 57.9 (SD 12.6) years, 933 (38.6%) were female, and 429 (17.7%) had received invasive mechanical ventilation. 1785 had measures at both timepoints, of which 240 (13.4%), 1138 (63.8%) and 407 (22.8%) were frail, pre-frail and robust, respectively, at 5 months compared with 123 (6.9%), 1046 (58.6%) and 616 (34.5%) at 1 year. Factors associated with pre-frailty or frailty were invasive mechanical ventilation, older age, female sex, and greater social deprivation. Frail participants had a larger reduction in HRQoL compared with before their COVID-19 illness and were less likely to describe themselves as recovered. Interpretation: Physical frailty and pre-frailty are common following hospitalisation with COVID-19. Improvement in frailty was seen between 5 and 12 months although two-thirds of the population remained pre-frail or frail. This suggests comprehensive assessment and interventions targeting pre-frailty and frailty beyond the initial illness are required. Funding: UK Research and Innovation and National Institute for Health Research
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study
No full textBackground: People with diabetes are at increased risk of hospitalisation, morbidity, and mortality following SARS-CoV-2 infection. Long-term outcomes for people with diabetes previously hospitalised with COVID-19 are, however, unknown. This study aimed to determine the longer-term physical and mental health effects of COVID-19 in people with and without diabetes. Methods: The PHOSP-COVID study is a multicentre, long-term follow-up study of adults discharged from hospital between 1 February 2020 and 31 March 2021 in the UK following COVID-19, involving detailed assessment at 5 and 12 months after discharge. The association between diabetes status and outcomes were explored using multivariable linear and logistic regressions. Findings: People with diabetes who survived hospital admission with COVID-19 display worse physical outcomes compared to those without diabetes at 5- and 12-month follow-up. People with diabetes displayed higher fatigue (only at 5 months), frailty, lower physical performance, and health-related quality of life and poorer cognitive function. Differences in outcomes between diabetes status groups were largely consistent from 5 to 12-months. In regression models, differences at 5 and 12 months were attenuated after adjustment for BMI and presence of other long-term conditions. Interpretation: People with diabetes reported worse physical outcomes up to 12 months after hospital discharge with COVID-19 compared to those without diabetes. These data support the need to reduce inequalities in long-term physical and mental health effects of SARS-CoV-2 infection in people with diabetes. Funding: UK Research and Innovation and National Institute for Health Research. The study was approved by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the ISRCTN Registry (ISRCTN10980107)
Long COVID and cardiovascular disease: a prospective cohort study
No full textBackground
Pre-existing cardiovascular disease (CVD) or cardiovascular risk factors have been associated with an increased risk of complications following hospitalisation with COVID-19, but their impact on the rate of recovery following discharge is not known.
Objectives
To determine whether the rate of patient-perceived recovery following hospitalisation with COVID-19 was affected by the presence of CVD or cardiovascular risk factors.
Methods
In a multicentre prospective cohort study, patients were recruited following discharge from the hospital with COVID-19 undertaking two comprehensive assessments at 5 months and 12 months. Patients were stratified by the presence of either CVD or cardiovascular risk factors prior to hospitalisation with COVID-19 and compared with controls with neither. Full recovery was determined by the response to a patient-perceived evaluation of full recovery from COVID-19 in the context of physical, physiological and cognitive determinants of health.
Results
From a total population of 2545 patients (38.8% women), 472 (18.5%) and 1355 (53.2%) had CVD or cardiovascular risk factors, respectively. Compared with controls (n=718), patients with CVD and cardiovascular risk factors were older and more likely to have had severe COVID-19. Full recovery was significantly lower at 12 months in patients with CVD (adjusted OR (aOR) 0.62, 95% CI 0.43 to 0.89) and cardiovascular risk factors (aOR 0.66, 95% CI 0.50 to 0.86).
Conclusion
Patients with CVD or cardiovascular risk factors had a delayed recovery at 12 months following hospitalisation with COVID-19. Targeted interventions to reduce the impact of COVID-19 in patients with cardiovascular disease remain an unmet need
